NASDAQ · ALLK
Healthcare · Biotechnology
$0.33
Up+$0.00 (+0.21%)
Updated Aug 14, 2026, 4:49 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ALLK does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ALLK.
ALLK research
Company profile and research snapshot.
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 26, 2024 | JMP Securities | Market Outperform | — |
| Jul 18, 2024 | Jefferies | Hold | — |
| Jun 26, 2024 | JMP Securities | Market Outperform | — |
| Jun 20, 2024 | Cantor Fitzgerald | Neutral | — |
| Jan 17, 2024 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Apr 2, 2025
Allakos Inc. has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire Allakos for $0.33 in cash per share. The transaction is expected to close in May 2025.
GlobeNewswire Inc. · Feb 10, 2025
Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Allakos Inc. (NASDAQ: ALLK). Shareholders may be entitled to damages and corporate governance reforms.
GlobeNewswire Inc. · Aug 7, 2024
Allakos Inc. provided a business update, including the initiation of a Phase 1 trial for AK006 in chronic spontaneous urticaria and the completion of dosing in a healthy volunteer trial for the same drug. The company reported financial results for Q2 2024, with a decrease in R&D and G&A expenses and a net loss of $26.7 million.
GlobeNewswire Inc. · Jun 25, 2024
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile –
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALLK.
No results
No recent SID articles mention ALLK.
